Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of... | June 3, 2023

Related Keywords

Chicago ,Illinois ,United States ,American ,Markus Renschler ,Linkedin ,Exchange Commission ,American Society Of Clinical Oncology ,Cyteir Therapeutics Inc ,Twitter ,Cyteir Therapeutics ,Monocarboxylate Transporter ,Advanced Solid ,Clinical Oncology ,Chief Executive Officer ,Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Gas ,Remonstrated ,Early ,Activity ,N ,Combination ,Ith ,Capecitabine ,Dr ,Gemcitabine ,Dvanced ,Olid ,Rumors ,End ,Igenerally ,Fell ,Ctolerated ,Safety ,Profile ,Heavily ,Pretreated ,Opulation Cyt Us23284p1030 ,